Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $11.96 million versus the consensus estimate of $9.05 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.